1. Generics Bulletin
  2. >>Products

Pfizer Calls For Sustainable Approach To Ensure Viability Of Biosimilars Market

Changes Are Needed To Best Capitalize On Opportunities For Savings From Biosimilars

 
• By Dave Wallace

Global biosimilars player Pfizer is calling for a more sustainable approach to the market to ensure its long-term viability. In the second part of an exclusive interview, Barry Chester, the firm’s global commercial lead for supportive care oncology, tells Generics Bulletin where the company sees room for improvement.

Sustainability compass arrow
Biosimilars market sustainability is a key focus for Pfizer • Source: Shutterstock

Having in the first part of his interview with Generics Bulletin spoken about how biosimilars fit into Pfizer’s wider business, the second part saw Barry Chester, the firm’s global commercial lead for supportive care oncology, reflect on the obstacles to biosimilar market sustainability and how these can be overcome.

Touching on recent US experiences with Humira biosimilars – that saw adalimumab rivals struggle initially to capture meaningful market share (Also see "Generics Bulletin Explains: One Year On, US Humira Biosimilars Continue To Struggle For Share" - Generics Bulletin, 31 January, 2024

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Amgen Locked Out Of Canadian Eculizumab Market Until 2027

 
• By Dean Rudge

Rejecting Amgen’s challenges on the grounds of anticipation and obviousness, Canada’s Federal Court has issued an injunction against the biosimilars firm until patent expiry in March 2027.

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

More from Leadership